Uncategorized - August 6, 2014
Big interest for AstraZeneca summer research school
The interest for AstraZeneca’s summer research school 2014 that started at Gothenburg University on August 4 has been high reports the company. The waiting lists have been long and the school were out of vacancies quickly, according to AstraZeneca. 53 students aged 14-17 participates in laboratories, lessons and study visits which are held at the laboratories of […]
Agreement - July 30, 2014
AstraZeneca signs deal with Almirall
AstraZeneca agrees strategic transaction with Almirall in respiratory disease. AstraZeneca has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. Also, AstraZeneca has agreed to make various sales-related payments. Upon completion […]
Collaboration - July 29, 2014
AstraZeneca in new collaborations
AstraZeneca has entered a new collaboration with Dutch Qiagen and a partnership with Roche. The company has entered into a collaboration with Netherlands-based Qiagen to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks […]
Uncategorized - July 27, 2014
AstraZeneca presents design for new R&D centre
AstraZeneca has revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. “We are very excited to be able to reveal the plans for our new site in Cambridge today. Our aim is to create an open, welcoming and vibrant centre that will inspire our teams and partners […]
Agreement - June 13, 2014
AstraZeneca in lisence agreement for asthma project
The company has entered a global lisence agreement with Synairgen Plc, an AIM-listed UK company specialising in respiratory diseases. The agreement regards SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. AstraZeneca will pay Synairgen a $7.25 million up-front fee and potential development, regulatory and […]
Agreement - June 4, 2014
AstraZeneca and Episentec in research agreement
The two companies have signed a research collaboration agreement for the development and implementation of improved methodology for early screening of potential new drug molecules. The research project will be aimed at an undisclosed drug target protein and will be utilizing the proprietary Label-Enhanced SPR biosensor technology of Episentec. Under the agreement, AstraZeneca will supply target protein and […]
